Our report, together with the clinical outcome of a patient from other centers, suggests that the combination of the third-generation EGFR-TKIs and pyrotinib has the potential to achieve long-term survival in EGFR-mutant/HER2-amplified NSCLC patients. Here, ERBB2 is linked to non-small cell lung carcinoma.